Komori
Sysmex (6869) · InitiativeFirst stated

Early diagnosis of primary aldosteronism using HISCL

First written in FY2026. . Latest entry: FY2026.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Launch of a diagnostic reagent for primary aldosteronism using the HISCL immunoassay systemA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2026First statedAnnual report

    「In November 2025, we began selling in Japan the immunoassay reagents “HISCL™ Aldosterone Reagent” and “HISCL™ Renin Reagent,” which support the early diagnosis of primary aldosteronism, one of the causes of hypertension. An estimated approximately 5% to 10% of hypertension patients in Japan have primary aldosteronism.」

    We began selling aldosterone and renin reagents in Japan for the HISCL series, launching a new application to support the early diagnosis of primary aldosteronism and the determination of treatment strategies. Primary aldosteronism is estimated to affect approximately 5% to 10% of hypertension patients in Japan.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Sysmex yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Early diagnosis of primary aldosteronism using HISCL | SYSMEX CORPORATION (6869) | Komori